Categories: HealthcareNews

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project

DXS INTERNATIONAL PLC (AQSE: DXSP)

ExpertCare featured in Innovate UK Research Project

DXS International plc (“DXS” or “the Company”), a leading provider of digital clinical decision support solutions, is thrilled to announce that its leading-edge digital health solution, ExpertCare, has been independently reviewed by the prestigious York Health Economics Consortium (YHEC) with results that confirm its powerful impact on both clinical outcomes and NHS cost-efficiency. 

Funded by DXS and Innovate UK and delivered in partnership with Health Innovation East, the evaluation assessed ExpertCare’s effectiveness in supporting medicines optimisation for patients with hypertension. The study, involving 2,484 patients across 13 UK GP practices, compared ExpertCare against standard hypertension review for GP practices. 

The evaluation found that ExpertCare delivers more effective hypertension control, reduces treatment variability, and is cost-saving in both the short and long term. 

The YHEC report concluded that: 

  • ExpertCare significantly increases the number of patients with optimally managed hypertension. 
  • For every £1 invested, ExpertCare returns £2.70 to the NHS. 

ExpertCare functions as an intelligent clinical decision support tool, streamlining data collection and generating treatment recommendations aligned with NICE guidelines—freeing up clinical time and improving outcomes at scale. 

David Immelman, CEO of DXS, commented: 

“We are incredibly proud of the results of this independent validation. It affirms our belief that ExpertCare has the potential to materially improve hypertension management across England, while reducing the cost burden on the NHS. These results highlight the real-world value of deploying ExpertCare nationally starting from year one.” 

For more information, please visit  

Contacts:

David Immelman

DXS International plc

www.dxs-systems.com

 

01252 719800
AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce

020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Attachment

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

4 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

4 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

4 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

4 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

4 hours ago